Published Date: 10 May 2024
Complete responses were seen in 75% of patients, and these were generally found to be long-lasting.
Read Full NewsFormer UK prime minister Rishi Sunak has called for a targeted prostate cancer screening program for men most at high risk of the disease, reviving a national debate on how to save more lives and tackle health inequalities ...
In recent research, treatment with osimertinib plus a platinum–pemetrexed chemotherapy combination resulted in statistically significant and clinically meaningful improvement in overall survival in patients with newly diagnosed ...
About half of women over 40 have dense breasts. The denser the breast tissue, the more difficult it is to spot cancer on a standard mammogram. Having dense breast tissue can make it harder to detect cancer and sometimes leads ...
Researchers from Rutgers Health and other institutions have discovered why a powerful leukemia drug eventually fails in most patients—and found a potential way to overcome that resistance.
1.
Base-edited T-cell therapy offers additional hope for treating resistant leukemia.
2.
Hybrid imaging test combines antibody and radioisotope for early lung cancer detection
3.
Maintenance Rituximab Improves Survival in Elderly MRD-Negative MCL Patients.
4.
Using MRD Status to Deescalate Multiple Myeloma Therapy
5.
Sydney researchers identify new tools to improve cancer diagnosis and treatment.
1.
Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer
2.
Polycythemia Vera: A Historical Perspective and Contemporary Management
3.
HCC in Melanoma: Role of HCC Codes and Moderate Whole Body Hyperthermia
4.
Revolutionizing Cancer Care: The Impact of Darzalex Faspro
5.
Survivin as a Key Regulator in Gynecological Cancers: Therapeutic and Prognostic Implications
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion
2.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part V
3.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II
4.
Understanding the causes of anemia in adults beyond nutritional deficiencies
5.
Managing CNS diseases at the point of diagnosis in ALK + NSCLC
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation